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Serial prophylactic exchange blood
transfusion in pregnant women with sickle
cell disease (TAPS-2): study protocol for a
randomised controlled feasibility trial
Laura L. Oakley1,2* , Moji Awogbade3, Sarah Brien4, Annette Briley5,6, Maria Chorozoglou7, Emma Drasar8,
Jemma Johns3, Elizabeth Rhodes9, Vicky Robinson5, Paul Seed10, Joseph Sharif11, Claire Singh5, Paul Telfer12,
Hilary Thompson5, Ingrid Watt-Coote9, Jo Howard5,13 and Eugene Oteng-Ntim1,5,10
Abstract
Background: Pregnancies in women with sickle cell disease (SCD) are associated with a higher risk of sickle and pregnancy
complications. Limited options exist for treating SCD during pregnancy. Serial prophylactic exchange blood transfusion
(SPEBT) has been shown to be effective in treating SCD outside pregnancy, but evidence is lacking regarding its use during
pregnancy. The aim of this study is to assess the feasibility and acceptability of conducting a future phase 3 randomised
controlled trial (RCT) to establish the clinical and cost effectiveness of SPEBT in pregnant women with SCD.
Methods: The study is an individually randomised, two-arm, feasibility trial with embedded qualitative and health
economic studies. Fifty women, 18 years of age and older, with SCD and a singleton pregnancy at ≤ 18 weeks’
gestation will be recruited from six hospitals in England. Randomisation will be conducted using a secure online
database and minimised by centre, SCD genotype and maternal age. Women allocated to the intervention arm will
receive SPEBT commencing at ≤ 18 weeks’ gestation, performed using automated erythrocytapheresis every 6–10
weeks until the end of pregnancy, aiming to maintain HbS% or combined HbS/HbC% below 30%. Women in the
standard care arm will only receive transfusion when clinically indicated. The primary outcome will be the recruitment
rate. Additional endpoints include reasons for refusal to participate, attrition rate, protocol adherence, and maternal and
neonatal outcomes. Women will be monitored throughout pregnancy to assess maternal, sickle, and foetal
complications. Detailed information about adverse events (including hospital admission) and birth outcomes will be
extracted from medical records and via interview at 6 weeks postpartum. An embedded qualitative study will consist
of interviews with (a) 15–25 trial participants to assess experiences and acceptability, (b) 5–15 women who decline to
participate to identify barriers to recruitment and (c) 15–20 clinical staff to explore fidelity and acceptability. A health
economic study will inform a future cost effectiveness and cost-utility analysis.
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Discussion: This feasibility study aims to rigorously evaluate SPEBT as a treatment for SCD in pregnancy and its impact
on maternal and infant outcomes.
Trial registration: NIH registry (www.clinicaltrials.gov), registration number NCT03975894 (registered 05/06/19); ISRCTN
(www.isrctn.com), registration number ISRCTN52684446 (retrospectively registered 02/08/19).
Keywords: Sickle cell disease, Pregnancy, Blood transfusion, Feasibility, Randomised controlled trial, Economic
evaluation, Qualitative
Background
Sickle Cell Disease (SCD) is one of the most common inher-
ited diseases worldwide [1]. It is characterised by anaemia,
intermittent unpredictable episodes of severe pain (vaso-oc-
clusive crisis) and chronic complications including stroke,
retinopathy, chronic lung disease, pulmonary hypertension
and renal dysfunction [2]. Pregnancy in women with SCD is
associated with an increased risk of sickle-related complica-
tions (pain crises, pulmonary complications, infection), as
well as a higher risk of maternal and perinatal mortality,
pregnancy-related complications (proteinuric hypertension,
venous thrombosis, caesarean delivery) and perinatal compli-
cations (intrauterine growth restriction, preterm birth and
low birthweight) [3, 4]. More than 300,000 children are born
with the disease annually worldwide [5], most in sub-
Saharan Africa. In 2016–17, 274 infants with SCD were born
in the United Kingdom [6]. In countries with advanced med-
ical care, most children will survive to adulthood [1], with
good expectation of having their own families. In the United
Kingdom, an estimated 15,000 individuals live with SCD,
with approximately 110 pregnancies in women with SCD
each year [3]. Despite obstetric interventions and improved
supportive care, these pregnancies have high rates of compli-
cations, with a persisting relative risk of maternal mortality of
14.26 (95% CI 7.52–27.07) [4]. Pregnancy in women with
SCD is also associated with recurrent hospital and critical
care admissions with inherent associated costs [3]. Currently,
only two disease-modifying treatments are available for pa-
tients with SCD: hydroxycarbamide and blood transfusion.
The former has a risk of teratogenicity and is not recom-
mended during pregnancy [7]. Blood transfusion is an im-
portant treatment in SCD and, outside pregnancy, has
proven efficacy in the treatment of acute sickle complications
and for the prevention of pain, acute chest syndrome and
neurological complications [1]. Blood transfusion can be
given as a simple or ‘top-up’ transfusion, which will improve
haemoglobin (Hb) levels and oxygen carriage and offer a
moderate decrease in red cells containing sickle Hb. The al-
ternative approach is exchange transfusion, i.e., the sequential
removal of patient red blood cells and replacement with
donor red cells; this produces a more marked reduction in
red blood cells containing sickle Hb. This can be undertaken
manually or using automated apheresis. Automated serial
prophylactic exchange blood transfusion (SPEBT) is the
preferred mechanism of long-term transfusion therapy.
SPEBT has proven results in improving clinical and cost ef-
fectiveness, as it is required less frequently than simple or
manual exchange transfusion and results in better control of
the haemoglobin, sickle percentage and reduced iron loading
[8]. During pregnancy, current clinical care requires that
transfusion be administered for emergency indications, such
as for symptomatic anaemia or acute chest syndrome [7].
Summary of findings from previous clinical trials and
systematic reviews
The role of blood transfusion in pregnant women with
SCD was investigated by a Cochrane review in 2016 [9].
This review identified one US trial published in 1988 in-
volving 72 women randomised to serial prophylactic
transfusion versus standard care (transfusion for clinical
indications only) [10]. The authors reported decreased
pain episodes in the group receiving serial prophylactic
transfusion, and whilst it detected no differences in
other maternal and neonatal complications, it was
underpowered to do so [10]. Women were enrolled up
to 28 weeks’ gestation, with a mean time of first transfu-
sion of 14 weeks, and patients were treated with serial
simple or partial exchange transfusion to maintain Hb
between 100 and 110 g/dl and HbS% below 35%. The
Cochrane review concluded that insufficient evidence
existed to provide reliable advice for an optimal blood
transfusion policy for pregnant women with SCD and
recommended a more rigorous randomised controlled
trial (RCT) to address this question. Another systematic
review and meta-analysis published in 2015 [11] identi-
fied 11 cohort studies, in addition to the RCT described
above. Meta-analysis of these studies showed that
prophylactic transfusion was associated with a reduction
in maternal mortality (OR 0.23; 95% CI 0.06–0.91), vaso-
occlusive pain episodes (OR 0.26, 95% CI 0.09–0.76),
pulmonary complications (OR 0.25, 95% CI 0.09–0.72),
preterm birth (OR 0.59, 95% CI 0.37–0.96) and perinatal
mortality (OR 0.43, 95% CI 0.19–0.99). Overall event
rates were low, and the studies had a high risk of bias
because of confounding and low event size; therefore,
the benefits of prophylactic transfusion may have been
overestimated. The authors concluded that a multicentre
RCT is needed to determine whether the potential
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benefits of SPEBT outweigh the associated risks. We
have identified one further study published since this
systematic review: an observational study, comparing
outcomes in 24 pregnancies in women with HbSC for
whom 10 received SPEBT and 14 received standard care
[12]. The standard care group experienced higher fre-
quencies of SCD-related complications (36% vs 10%),
and these complications were more severe. All cases of
acute chest syndrome (n = 4) occurred in the standard
care group. A statistically significant difference was ob-
served in the gestational age at birth (38.7 weeks in the
transfusion group vs 34.4 weeks in standard care), and a
higher frequency of preterm births was observed in the
standard care group (69% vs 30%). The authors con-
cluded that a reduction of adverse outcomes occurred in
the patients who received SPEBT, although the study
was limited by a small sample size.
Significant knowledge gaps exist regarding the effect-
iveness of SPEBT for pregnant women with SCD [9, 11],
and a recent survey of 90 clinicians providing care to
pregnant women with SCD reported that 94% (n = 85)
supported the need for a RCT to assess the benefits of
SPEBT in this population [13]. A detailed search of trial
registries including UKCRN, ISRCTN, Clinical Trials.gov
and European Union Clinical Trial registry showed no
registered current trials on transfusion in pregnant
women with SCD. The proposed research, designed in
conjunction with PPI representatives, clinical staff and
other stakeholders, has the potential to improve the evi-
dence base regarding the management of pregnant
women with SCD.
Methods/Design
Aim
The aim of the current study is to assess the feasibility
and acceptability of conducting an RCT to establish the
clinical and cost effectiveness of serial prophylactic ex-
change blood transfusion (SPEBT) in pregnant women
with SCD. The detailed objectives of the study are
shown in Table 1.
Design and setting
This is a UK, multicentre, randomised, two-arm, feasibility
trial with embedded qualitative and economic studies.
Participants
The participants are women ≥18 years of age with SCD
(all genotypes, with confirmatory laboratory results) and
a singleton pregnancy at < 18+ 0 weeks’ gestation.
Exclusion criteria
Women will be ineligible if any of the following criteria
apply:
 Unable or unwilling to give written informed
consent
 On long-term transfusion programme prior to preg-
nancy for the amelioration of SCD
 Unable to receive blood transfusion for social,
clinical or religious reasons
 Current diagnosis of major medical or psychiatric
comorbidity that, in the randomising clinicians’
opinion, renders them unable to enter the trial
 Prior hyperhaemolysis
 Red cell phenotype or antibodies present prevent
likely provision of adequate red cell units to support
elective EBT programme
Participant identification and recruitment
Potentially eligible women with SCD will receive a verbal
explanation of the study and will be given the Patient In-
formation Sheet (PIS) at either the SCD clinic or at the
first antenatal clinic appointment at participating hospi-
tals (Fig. 1). Women who are interested in participating
will be invited to meet the research midwife prior to
18+ 0 weeks’ gestation to fully assess eligibility and an-
swer any queries. If the woman decides to participate,
written informed consent will be obtained by one of the
trial physicians on the study delegation log. Participants
have the right to withdraw at any time without giving a
reason. The number of women approached, eligible and
declining participation (when first approached or at con-
sent), and the reasons for non-participation will be col-
lected via the secure Internet-based study database
(MedSciNet™). The schedule of procedures for the study
is presented in Fig. 2.
Randomisation
Randomisation will be achieved via the study-specific
Internet-based secure data management system (MedS-
ciNet™), which is the repository for all trial data. The
unit of randomisation will be the individual participant,
allocated in a ratio of 1:1 to intervention and standard
care. Participants will be randomised using minimisa-
tion, balancing on centre, SCD genotype and maternal
age. Participants will be present at the time of random-
isation and will be informed of their allocation. Blinding
of the participants or the attending care teams will not
be possible due to the nature of the intervention.
Standard care
All participants will receive routine NHS antenatal care
for pregnant women with SCD based on the NICE
accredited RCOG Guidelines [7] and in accordance with
local policies in the participating units. This will include
multidisciplinary care, involving obstetricians, haematol-
ogists and midwives, prophylactic folic acid to improve
anaemia, penicillin to reduce the risk of infection and
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low-dose aspirin. Women in the standard care group will
only receive a blood transfusion where clinically
indicated.
Intervention
Women allocated to the intervention will receive SPEBT
starting between 6+ 0–18+ 0 weeks of gestation. SPEBT
will be performed using automated apheresis technology,
approximately every 6–10 weeks until the end of preg-
nancy, aiming to maintain HbS% below 30% or com-
bined HbS and HbC below 30%. The procedure will be
carried out in accordance with local practices on the
haematology day unit or the antenatal day ward by the
clinical or research nurse/midwife, haematology day unit
staff or specialist sickle nursing staff, using standard op-
erating procedures. Where peripheral venous access is
not possible, femoral line access will be used. Blood tests
(full blood count, HbS%, group and screen) will be car-
ried out 1–3 days prior to the procedure and immedi-
ately post-procedure in accordance with local guidelines
and practice. The number of red cell units used per
transfusion will depend on the patient weight and pre-
transfusion HbS% but will usually be between 6 and 8
units on each occasion of transfusion.
Data collection
All baseline and follow-up data will be entered on the
secure internet-based data management system contem-
poraneously, with the exception of pregnancy outcome
follow-up, which will be updated postnatally. Additional
data will be extracted from NHS medical records and
entered directly onto the system by members of the
research team. This will negate the need for paper clin-
ical research files and will minimise errors in transcrip-
tion, whilst facilitating expedient data monitoring and
cleaning. Once data collection is complete, the trial team
at the lead centre (GSTT) will have access to the final
trial dataset, and analyses will be led by the appointed
trial statistician.
At baseline, information will be collected on previous
medical and obstetric history, current pregnancy, socio-
demographic information and quality of life (QOL) data.
All participants will be seen every 4 to 6 weeks during
pregnancy at the specialist sickle–obstetric clinic or the
high-risk obstetric clinic to assess and record maternal,
sickle and foetal complications. Health economic data
will be collected at least once per trimester using the 3 L
and 5 L Euroquol EQ-5D questionnaires [14]. Following
the birth, detailed information regarding health in late
pregnancy, labour and birth, postnatal complications, ad-
missions to higher levels of care and length of maternal
hospital stay will be extracted from NHS medical re-
cords. Neonatal data will include the need for resuscita-
tion, Apgar scores, admission to NICU/SCBU, feeding
method and duration of hospital stay (in each level of
care). At 6 weeks postpartum, participants will be invited
to an appointment with the research team to provide in-
formation about their and their infant’s postpartum
complications and health. QoL data will also be col-
lected. If a visit is not feasible, a telephone interview will
be conducted. A subset of study participants will be
interviewed to assess views and experiences of trial par-
ticipation. Postnatal medical records will also be
reviewed if available.
Table 1 Detailed study objectives by sub-study
Objectives
Trial Feasibility: primary 1. Assess the willingness of pregnant women with SCD to take part in a randomised controlled trial comparing
SPEBT to standard care.
Feasibility:
secondary
2. Identify barriers and facilitators to participation in the trial, including assessing reasons for refusal.
3. Assess retention rates of participants throughout pregnancy in both arms of the study.
4. Assess the willingness of clinicians to recruit into this trial.
Clinical: infant 5. Assess the proportion from the control arm advised clinically to start prophylactic blood transfusion.
6. Measure clinical outcomes for women and infants including an initial preliminary assessment of efficacy for
future definitive trial.
7. Generate data to inform the design of a definitive trial, including identifying the primary outcome.
Clinical: maternal
Safety 8. Record safety issues around blood transfusions in both arms of the study
Qualitative Feasibility 9. Identify barriers and facilitators to participation from study participants, clinicians and, where possible, those
unwilling to participate
10. Identify strategies to optimise recruitment and retention
11. Assess acceptability of the intervention, trial procedures and study conduct, including identifying the core
outcomes that are considered important to measure and preference for either HRQOL measure
12. Identify reasons for attrition
13. Assess women’s experience of taking part in the study
Economic Resource Use &
Costs
14. Explore the cost implications of the proposed intervention and to assess measurement tools and methods
HRQoL & health
benefits
15. Assess two widely used HRQoL measures against each other and other health benefits
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Outcomes
Primary outcome
The primary outcome is the efficacy of recruitment
strategy, measured by comparing the number of re-
cruited and randomised women with the total number
of eligible women in all centres.
Secondary outcomes
We will measure the following secondary feasibility
outcomes:
 The number of women screened who meet the
study eligibility criteria
 Reasons for eligible women declining participation
 Rate and reasons for attrition (monitored by
assessing the number of women completing the
study, and by reporting reasons given (if any) for
study drop-out)
 Protocol adherence (measured by the number of
women allocated to the intervention group who
receive SPEBT as intended (beginning < 18 weeks,
transfusions every 6–10 weeks, to maintain a HbS <
Fig. 1 Study flowchart
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Fig. 2 Schedule of enrolment, interventions, and assessments for TAPS2
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30% or combined HbS & HbC < 30%), and the
number of women in the standard care group who
receive a transfusion due to clinical need)
 Patient experience and acceptability (assessed
through qualitative methods)
 Views and experiences of clinical staff caring for
women in both arms of the trial (assessed through
qualitative methods)
The following clinical outcomes will also be measured:
 Neonatal: Foetal demise/stillbirth/neonatal death,
Apgar score at 5 min, birthweight, gestation at birth,
NICU/SCBU admission with reason and length of
stay, feeding method at discharge
 Maternal: Antenatal hospital admissions and critical
care admissions, length of stay (total inpatient,
antenatal and postnatal nights), frequency and
severity of painful crisis (severity of crisis will be
measured as mild, moderate, severe or extremely
severe, where mild crises may or may not have
required pain medication but did not prevent
normal activity, moderate crises required medication
and caused significant changes in daily activities,
severe crises required attendance at hospital, and
extremely severe required hospital admission); use of
opioid analgesics (excluding labour); frequency of
SCD-related complications (acute chest syndrome,
pre-eclampsia); number and reason for any transfu-
sion (in the standard care arm); number of transfu-
sions (in the intervention arm), mode of birth, and
estimated blood loss; postnatal health and complica-
tions, including pain and primary and secondary
postpartum haemorrhage; and hospital readmission
after postnatal discharge, thromboembolism, infec-
tion, or depression
We will additionally collect data on the following
safety outcomes: transfusion reactions, alloimmunisation
and delayed haemolytic transfusion reaction.
Health economic sub-study
Alongside this feasibility RCT, we will conduct a health
economic sub-study to inform a future cost effectiveness
and will conduct a cost-utility analysis within our defini-
tive RCT. We will collect data using two preference-
based QoL measures, with the aim of identifying the
most suitable HRQoL instrument. We plan to address
the following research questions: what are the cost im-
plications of SPEBT in pregnant women with SCD (com-
parison of costs of both treatment options compared to
widely-used NHS Reference Costs), and, what are the
implications of using differing cost methods when asses-
sing the cost effectiveness of the intervention?
Nested qualitative study
A nested qualitative study aims to capture the views and
experiences of both participants and clinical staff in-
volved in the study to inform the design of a definitive
trial. Face-to-face semi-structured interviews will be con-
ducted postnatally with 15–25 women recruited to both
study arms; telephone interviews will be conducted if
face-to-face interviews are not possible. Participants will
be purposively sampled, using a maximum variation
sampling approach on key characteristics (e.g., those
who completed versus those who dropped out, across
different recruitment sites). Interviews will explore the
acceptability of randomisation and study conduct (trial
appointments, measurements and blood tests and re-
cruitment/retention). In addition, participants in the
intervention arm will be asked for their perception and
experience of SPEBT (e.g., timings, regime, adverse ef-
fects) and the impact of the intervention on their daily
life. We will also conduct 5–15 short telephone inter-
views with women who declined participation in the
study. These interviews will explore barriers to participa-
tion, helping to identify strategies to enhance recruit-
ment in a future trial. In addition, interviews with 15–20
clinical staff considered ‘key informants’ (e.g., research
nurses/midwives, sickle nurse specialists, sickle haema-
tologists and sickle obstetricians in each centre) will ex-
plore fidelity and acceptability. Written informed
consent for the qualitative study for trial participants will
be obtained prior to contact by the researcher, and con-
sent will be reaffirmed immediately prior to interview.
For clinicians and for those women who were
approached but who did not take part in the trial, writ-
ten informed consent will be obtained before the inter-
view commences. All interviews will be digitally
recorded verbatim, transcribed and analysed using the-
matic analysis within and across individual interviews,
using the constant comparison approach to identify
themes and subthemes. Standard methods will be
employed to ensure rigour (e.g., audit trail, reflexive
diaries, double coding etc). We will follow recent guid-
ance regarding the effective use of qualitative research in
feasibility studies for RCTs [15].
Trial withdrawal or discontinuation
We will withdraw participants if they lack the capacity
to provide ongoing consent. Participants have the right
to withdraw from the study at any time, without giving a
reason. The PI and local investigators will also have the
right to withdraw patients from the study intervention in
the event of inter-current illness, AEs, SAEs, SUSARs,
protocol violations, administrative reasons or other rea-
sons. Women who wish to withdraw from the trial will
be asked to confirm whether they are still willing to
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provide routine follow-up data and/or participate in in-
terviews (assessed as per intention to treat).
The trial may be prematurely discontinued by the
Sponsor, Chief Investigator or Regulatory Authority on
the basis of new safety information or for other reasons
given by the Trial Steering Committee (TSC), regulatory
authority or ethics committee concerned. If the trial is
prematurely discontinued, active participants will be in-
formed, and no further participant data will be collected.
The Competent Authority and Research Ethics Commit-
tee will be informed within 15 days of the early termin-
ation of the trial.
Power and sample size
The study is designed to establish the rates at which
women with SCD can be recruited and retained in a fu-
ture definitive RCT. A sample of 40 women (20 in each
arm) will allow us to estimate the overall recruitment
rate per woman with SCD to within 10% of the true
value. This approach will accurately predict the recruit-
ment rate in the main study and determine the required
length of the recruitment period.
Over an 18-month recruitment period, we estimate
that a total of approximately 100 women with SCD will
be seen in participating maternity units. Assuming a 50–
60% recruitment rate (allowing for ineligible women and
those who do not wish to take part), we plan to recruit
50 participants during the study period (25 in each arm).
Allowing for a 20% loss to follow-up, we estimate that
40 women should complete postpartum follow-up, con-
sistent with our required sample size.
Analysis
Our primary outcome (overall recruitment rate as a per-
centage of eligible women) will be estimated using the
Clopper-Pearson exact Binomial method for a 95% con-
fidence interval. The number of women screened, eli-
gible, consented, randomised and withdrawn from the
study will be reported by site, and overall numbers sum-
marised as a CONSORT flow diagram. Reasons for ex-
clusion and for withdrawal will be summarised.
Descriptive statistics including 95% confidence intervals
will be presented for all baseline data and clinical out-
comes, with a focus on estimates of standard deviation
necessary to perform sample size calculations for a fu-
ture trial. Although the study is expected to be under-
powered for clinical outcomes, differences in clinical
outcomes will be presented as an initial assessment of
efficacy and safety of this treatment, and for inclusion in
any future meta-analysis. All analyses will be based on
the intention-to-treat (ITT) principle. The trial will be
reported in accordance with the CONSORT guidelines
on randomised feasibility studies [16].
Ethical considerations and confidentiality
The trial will be conducted in compliance with the prin-
ciples of the Declaration of Helsinki (1996), the princi-
ples of GCP and in accordance with all applicable
regulatory requirements including the Research Govern-
ance Framework. NHS ethics approval has been ob-
tained for all centres from the London and Surrey
Borders Research Ethics Committee. Written informed
consent for trial participants will be obtained by one of
the trial physicians, with written informed consent ob-
tained separately for qualitative interviews.
Blood transfusions are regularly used in the clinical
care of women with SCD during pregnancy. The most
common risk of transfusion is minor reactions such
as skin rash or a minor fever, with some reactions
(light-headedness, tingling sensation on lips and fin-
gers) specific to the exchange transfusion due to the
anticoagulant used. More serious complications in-
clude haemolytic transfusion reaction, alloimmunisa-
tion and delayed transfusion reaction. We will record
all adverse events resulting from the apheresis inter-
vention; for example, issues with venous access and
citrate toxicity and serious adverse events (SAEs) will
be reported to the Sponsor and REC. Additionally, all
participating sites will be expected to follow local and
national guidance with respect to the severity of the
reaction; this could include but will not be limited to
appropriate level and immediacy of medical care,
reporting to SHOT (Serious Hazards of Transfusion)
and MHRA as well as notification through the local
risk management system to enable thorough investiga-
tion of the incident.
All trial data will be stored on a secure password-
protected study-specific database (MedSciNet™), compli-
ant with GDPR regulations. The database will hold min-
imal identifiers, with each participant being allocated a
unique study ID, and will only be accessible to
authorised members of the team. Identifiable data will
only be kept in order to facilitate communication with
participants. Once women have completed their partici-
pation (reached study end or withdrawn), patient identi-
fiable data will be destroyed in accordance with local
policies and GDPR.
Patient and public involvement
In developing the project proposal and protocol, we have
worked closely with a user panel of pregnant women
with SCD and with the Sickle Cell Society. A PPI group
comprising women with SCD has met throughout the
development phase and will continue to meet regularly
throughout the trial and the dissemination phase. This
group will assist with reviewing study documents for ac-
cessibility and data interpretation, as well as advising on
our dissemination strategy.
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Trial governance and monitoring
A Core Project Management Team (CPMT) consisting
of the Chief Investigator, co-investigators and the Project
manager will meet monthly to oversee the day-to-day
running of the trial. The CPMT will be responsible for
regular auditing of trial conduct and for communicating
important protocol modifications to the wider project
team. The TSC will include experts in the field of mater-
nal medicine and haematology and will meet every 6
months to provide overall supervision of the study, in-
cluding reviewing progress towards the study milestones
and advising the CPMT on any safety concerns, and to
contribute to recommendations regarding progression to
a definitive RCT. As this is a small feasibility trial, a sep-
arate data monitoring committee has not been con-
vened. The study sponsor is Guy’s and St. Thomas’ NHS
Foundation Trust (GSTFT). The trial may be subject to
audit by GSTFT under their remit as Sponsor.
Progression to a full trial
This feasibility study will provide evidence of whether a
definitive RCT could be undertaken. We will assess
whether women with SCD are prepared to be recruited
and randomised to a trial evaluating SPEBT, and we will
collect information on outcomes important to participat-
ing women and sickle nurse specialists and associated
care providers to inform the design of such a trial.
On completion of the feasibility study, we will use the
analysis of outcomes to link to progression criteria, ap-
plying a traffic light system (green: proceed, yellow: con-
sider changes, red: stop) as detailed in Table 2. Adequate
recruitment, acceptability of the intervention, fidelity
and reach, and retention will all be key to this assess-
ment. Where there is discordance in the findings within
the columns (for example, if we have green for the re-
cruitment rate but yellow for dose and red for retention),
then we will consider all available information, including
the qualitative study findings to guide our decision.
Throughout this process, we will work closely with our
Expert PPI group, TSC and key stakeholders.
Dissemination plans
The trial results will be published in peer-reviewed sci-
entific journals, and abstracts will be submitted to con-
ferences. The study final report will be circulated to
clinicians, service managers and commissioners through
the RCOG, the British Society for Haematology, and
NHS Clinical Commissioning Groups. A lay research
summary will be disseminated to user groups such as
the UK Haemoglobinopathy Forum and Sickle Cell Soci-
ety, and to research participants and patient groups at
collaborating hospitals.
Discussion
Significant knowledge gaps exist on the effectiveness of
SPEBT for pregnant women with SCD [9–11, 13]. This
trial will allow us to assess whether women with SCD
are prepared to be recruited and randomised to a defini-
tive trial evaluating SPEBT and will provide crucial in-
formation on the acceptability of such a trial. This
feasibility trial will enable us to collect information on
outcomes important to participating women and sickle
clinicians to inform the design of a definitive trial.
Practical issues for this trial include some elements of
recruitment, particularly whether women will find it ac-
ceptable to be randomised to SPEBT. Although the pro-
posed intervention is an invasive procedure with
associated risks, our PPI work suggests that women with
SCD who have experienced pregnancy feel that benefits
from SPEBT may outweigh its risks. We note that suc-
cessful studies of exchange transfusion have been con-
ducted in other populations [17, 18]. Another practical
issue for consideration is the potential difficulty in
obtaining venous access in women with SCD; however,
the participating centres all have well-established SPEBT
programmes and staff who are highly skilled in obtaining
peripheral venous access in this patient group. We are
aware of the increased alloimmunisation in this patient
group and will ensure that blood is matched for Rh and
Kell blood groups.
The proposed study will provide important evidence
about the feasibility of a definitive phase 3 trial of SPEBT
Table 2 ‘Traffic light’ criteria to assess progression to a full trial
Recruitment rate of eligible
participants (measuring
reach, acceptability)
Frequency of SPEBT
(measuring dose,
acceptability)
Retention until 6 weeks
post-delivery (measuring
acceptability)
Findings from qualitative study and acceptability
Green ≥ 50% ≥ 75%, three or
more
≥ 80% Progress but will use findings from qualitative study to
inform and improve definitive RCT
Yellow 30–50% 50–75%, three or
more
50–80% Use findings from qualitative study to inform progressing
to definitive study depending on guidance from trial
steering committee, Sickle Cell Society, PPI group and key
stakeholders
Red < 30% < 50%, three or more < 50% Will not progress
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in pregnant women, and the information collected
through the trial and qualitative and economic sub-
studies will be crucial in guiding the development of
such a trial.
Trial status
The protocol published here is version 1.1 dated 14 June
2019. The study began on 2 April 2019. Study recruit-
ment commenced on 1 July 2019 and is expected to
continue until 30 November 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4212-8.
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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